Marker Therapeutics
MRKR
64 hedge funds and large institutions have $25.1M invested in Marker Therapeutics in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 28 reducing their positions, and 9 closing their positions.
508% more call options, than puts
Call options by funds: $158K | Put options by funds: $26K
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
2% more funds holding
Funds holding: 63 → 64 (+1)
0% more ownership
Funds ownership: 3.18% → 3.19% (+0%)
44% less capital invested
Capital invested by funds: $44.7M → $25.1M (-$19.6M)
68% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$202K |
| 2 |
MAA
Matrix Asset Advisors
White Plains,
New York
|
+$199K |
| 3 |
Jane Street
New York
|
+$113K |
| 4 |
Renaissance Technologies
New York
|
+$111K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$52.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$402K |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$379K |
| 3 |
Two Sigma Advisers
New York
|
-$355K |
| 4 |
AAM
AR Asset Management
West Hollywood,
California
|
-$276K |
| 5 |
Norges Bank
Oslo,
Norway
|
-$180K |
MRKR Hedge Fund Activity: Q4 2021 in Review
64 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q4 2021, worth a combined $25.1M — down 44% from $44.7M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new MRKR positions and 9 closed out — a net gain of 1 holder — while 9 added to existing stakes and 28 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $202K. The largest seller was Two Sigma Investments, cutting an estimated $402K.
- 64 institutional investors held Marker Therapeutics (MRKR) as of Q4 2021, up from 63 in Q3 2021.
- Funds reported $25.1M of Marker Therapeutics stock for Q4 2021, down 44% quarter-over-quarter.
- 10 funds opened new Marker Therapeutics positions in Q4 2021 and 9 closed out, a net change of +1 holder.
- The largest Marker Therapeutics buyer in Q4 2021 was Susquehanna International Group, an estimated $202K added.
- The largest Marker Therapeutics seller in Q4 2021 was Two Sigma Investments, an estimated $402K sold.
Based on aggregated 13F filings for Q4 2021.